Warfarin withdrawal. Pharmacokinetic-pharmacodynamic considerations

Area of Science:

• Pharmacology
• Hematology
• Clinical Medicine

Background:

• Warfarin is a widely used oral anticoagulant with a narrow therapeutic index.
• Its efficacy and safety are influenced by genetic factors, drug interactions, and patient adherence.
• Discontinuation of warfarin therapy can lead to a 'rebound phenomenon,' characterized by a hypercoagulable state.

Purpose of the Study:

• To investigate the changes in markers of hypercoagulability after warfarin cessation.
• To compare the effects of abrupt versus gradual warfarin withdrawal on coagulation parameters.
• To assess the clinical relevance of the rebound phenomenon in patients with venous thromboembolism.

Main Methods:

• Prospective study involving 32 patients with venous thromboembolism.
• Randomized withdrawal of warfarin, either abruptly or gradually.
• Measurement of various markers of hypercoagulability, including fibrinopeptide A, activated factor VII, prothrombin fragments F1+2, thrombin-antithrombin complexes, and D-dimers.

Main Results:

• Interruption of warfarin treatment was found to frequently elicit a low-grade activation of blood coagulation.
• Increased levels of hypercoagulability markers were consistently observed after cessation of anticoagulation.
• The study provides evidence supporting the occurrence of a hypercoagulable state upon warfarin withdrawal.

Conclusions:

• Warfarin cessation can lead to a prothrombotic state, necessitating careful management.
• Monitoring coagulation markers post-discontinuation may help identify patients at increased risk of recurrent thromboembolism.
• Further research is warranted to elucidate the long-term implications and optimal management strategies for warfarin withdrawal.